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ABSTRACT
Background: The 2013–2016 Ebola epidemic in West Africa is the worst ever caused by 
Ebolaviruses with over 28,000 human cases and 11,325 deaths. The World Health Organisation 
(WHO) declared the epidemic a public health crisis that required accelerated development of 
novel interventions including vaccines. The Medical Research Council/Uganda Virus Research 
Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit (MRC/ 
UVRI & LSHTM Uganda Research Unit) was among the African research sites that implemen-
ted the VAC52150EBL1004 Ebola vaccine trial.
Objective: We report on the strategies utilised by the Unit and sponsor in ensuring expedited 
clinical trial approval and accelerated conduct.
Methods: Janssen Vaccines and Prevention B.V. conducted a phase 1 trial to evaluate the 
safety, tolerability, and immunogenicity of heterologous two-dose vaccination regimens 
using Ad26.ZEBOV and MVA-BN-Filo, in healthy adults in Africa. Accelerated implementation 
strategies are hereby presented.
Results: Strategies included: holding the African Vaccine Regulatory Forum (AVAREF) joint 
review meeting; expedited review by institutional ethics and country-specific regulatory 
bodies; competitive recruitment between sites; electronic data capture (EDC); frequent 
study monitoring schedule; involvement of a community advisory board (CAB); and utilization 
of a ‘phased’ study information-sharing approach in community engagement and participant 
recruitment. These strategies enabled the site to acquire approvals within 2 months and enrol 
47 participants within a spurn of five. The same milestone is usually acquired in at least 1 year 
without accelerated implementation.
Conclusion: The use of well-thought strategies by sponsors and research sites can enable the 
implementation of accelerated research. We recommend the use of similar strategies in other 
settings.
ARTICLE HISTORY
Received 6 July 2020  
Accepted 25 September 2020 
RESPONSIBLE EDITOR 
Stig Wall, Umeå University, 
Sweden 
KEYWORDS
Ebola virus disease; 
expedited approval; 
accelerated conduct; vaccine 
research
Background
The Ebola epidemic of 2013–2016 was the largest the 
world has ever experienced. Over 28,600 human cases 
and 11,325 deaths were reported across Guinea, Liberia, 
and Sierra Leone, during this period [1]. The epidemic 
was declared a public health crisis in August 2014 by the 
WHO [2] and necessitated accelerated development of 
novel interventions including vaccines [3]. WHO called 
for fast-track development of Ebola vaccines as part of the 
Ebola Response Roadmap [3] and further stressed in 
October 2014 that this was a public health priority [4,5]. 
A WHO panel considered the West African Ebola epi-
demic extraordinary for several reasons including, but 
not limited to, its magnitude, contagiousness and high 
lethality of the disease, and the additional burdens on 
fragile health systems. All these factors created an 
opportunity to investigate the disease during an epi-
demic. The occurrence of these factors led to the con-
sensus that clinical trials had to be conducted urgently 
[6]. Other international agencies such as the Wellcome 
Trust and Centre for Infectious Disease Research and 
Policy brought together experts from all over the world 
to support the initiative [7]. This collaboration estab-
lished a team of experts from different backgrounds to 
rapidly assess challenges and opportunities related to 
vaccine development, identify potentially overlooked 
aspects of the vaccine development process, and urgently 
synthesise information for distribution in the public 
health domain. Accelerated vaccine development was 
also partly possible because many vaccine candidates 
had already been evaluated in pre-clinical studies and 
many had shown good immunogenicity profiles [5,8].
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Subsequently, several clinical trials were conducted 
during and after the epidemic, many of which were 
multi-centre international projects using different 
vaccine candidates [9,10]. One of these was the 
VAC52150EBL1004 Ebola vaccine clinical trial spon-
sored by Jansen Vaccines and Prevention B.V. The 
trial was implemented at the MRC/UVRI & LSHTM 
Uganda Research Unit site in Masaka, and the 
Mwanza Intervention Trials Unit in Tanzania [11].
The accelerated implementation of such a research 
project in Africa was a new approach. It required 
implementation by well-established research institu-
tions and the use of forward-thinking research pro-
cesses to accelerate regulatory submissions, to foster 
robust community engagement, and to initiate and 
maintain participant recruitment, management, and 
follow up. This all happened in the context of a back-
ground characterized by mixed feelings including fear 
and scepticism about the use of Ebola vaccines, which 
had never been extensively used in humans [12–14]. 
Despite this situation, the sponsor together with the 
MRC/UVRI & LSHTM Uganda Research Unit was 
able to conduct the trial within the stipulated time-
lines. We believe that this accomplishment offers a 
learning opportunity for the implementation of similar 
projects in the future in this and other settings, espe-
cially where an accelerated approach may be required.
Methods
Trial design
VAC52150EBL1004 was a randomized, observer-blind 
placebo-controlled, trial evaluating the safety, tolerability, 
and immunogenicity of a two-dose vaccination regimen 
using Ad26.ZEBOV and MVA-BN-Filo administered in 
different sequences and schedules in healthy adults 
(based on clinical and laboratory parameters) [11]. The 
study enrolled participants aged ≥18 to ≤50 years, who 
were able to read and provide consent. Participants were 
excluded if HIV positive, pregnant or breastfeeding or 
planning to become pregnant within the study execution 
period. Other details on study eligibility, randomisation, 
blinding, vaccination, and follow up are published else-
where [11,15].
Briefly, the study consisted of a screening period of 
up to 28 days, a vaccination period in which partici-
pants were vaccinated on day one, followed by a 
second vaccination 4 or 8 weeks later and a post- 
dose 2 follow-up for 21 days, and thereafter follow up 
for up to 1 year after randomisation.
Study implementation at the Ugandan site
Regulatory approvals were attained within a spurn of 
approximately 2 months. The site study initiation 
visit was conducted on 6 March 2015, participant 
screening started on 20 April 2015, and the first 
participant was dosed on 4 May 2015. The site admi-
nistered the last participant with the second dose on 
10 November 2015. Enrolment took place across a 
spurn of 5 months (from the time screening started to 
the time the last participant was enrolled). The last 
participant completed follow up on 16 September 
2016 and the site study close-out meeting held on 
30 November 2017.
While it took a total of approximately 7 months 
to attain approval and complete enrolment, it nor-
mally takes a minimum of 1 year at the unit for a 
similar number of participants without accelerated 
implementation.
The mean age (standard deviation) of the 47 par-
ticipants enrolled was 25.4 years (5.3), with 34 
(77.3%) of these males and 13 (27.7%) females. All 
47 participants enrolled completed follow up.
Review of strategies for successful accelerated 
implementation
The study sponsor and the MRC/UVRI & LSHTM 
Uganda Research Unit utilised several strategies to 
enable accelerated implementation. The sponsor- 
initiated strategies included: 1) holding the AVAREF 
joint ethics, regulatory authority, investigator and spon-
sor review meeting, 2) advocating for expedited review 
by Institutional ethics and country-specific regulatory 
bodies, 3) competitive recruitment between sites, 4) 
electronic data capture, and 5) frequent study monitor-
ing. The MRC/UVRI and LSHTM Uganda Research 
Unit specific strategies included: 1) involvement of a 
community advisory board (CAB) and 2) ‘phased’ study 
information-sharing sessions in community engage-
ment and participant recruitment. These strategies are 
hereby discussed including details on how each was 
implemented, rationale for use, lessons learnt, and chal-
lenges faced while using the strategy. Appendix 1 is a 
flow diagram showing the number of participants at 
different stages of the study and the interplay of strate-
gies, while Appendix 2 is a table summarising the stra-
tegies, rationale for using them, the impact, lessons 
learnt, and challenges met while using them.
The AVAREF joint ethics, regulatory authorities, 
investigator and sponsor review meeting
This meeting took place on 3 and 4 February 2015 in 
Arusha, Tanzania. The objective was to allow joint 
preliminary review of the Janssen Ebola Zaire vaccine 
clinical trial applications by ethics and national reg-
ulatory authorities of the countries of Ghana, Kenya, 
Tanzania, and Uganda. The meeting involved presen-
tation of the study protocols by the sponsor and 
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response to questions raised by regulators and other 
stakeholders including the FDA. Implementing sites 
also made presentations to demonstrate their readi-
ness to conduct the studies. Finally, regulatory autho-
rities offered their recommendations and agreed 
upon a commitment to issue approval/non-approval 
within a certain timeframe, which informed amend-
ments to the study protocols and subsequent inde-
pendent ethics and regulatory review.
Rationale for the strategy
Previous reviews written about the regulatory pro-
cesses in Africa have shown that the region has sev-
eral of shortcomings in the conduct of these. 
Specifically, issues include prolonged timelines for 
reviews, disparities in procedures for reviews and 
authorizations, and duplication of roles within differ-
ent authorities [16,17]. The AVAREF network was 
formed as an informal capacity-building platform 
aimed at improving the regulatory oversight of inter-
ventional clinical trials being conducted in Africa 
[18]. Over the years, this platform has demonstrated 
its value in strengthening regulatory and ethics 
reviews, promoting harmonized standards and 
approaches, and accelerating the development of vac-
cines of high public health value. In the meeting held 
prior to the Ebola vaccine trials, external support was 
provided by the USA Food and Drug Administration, 
European Medicines Agency, and Health Canada. 
This support was necessary because the products 
that were about to be tested were new and complex, 
yet it was extremely necessary to have the studies 
conducted as soon as possible to offer solutions for 
the ongoing epidemic. The AVAREF process was also 
important in understanding the local and regional 
concerns, addressing them, and educating the wes-
tern partners on what was critical to conducting 
studies in the region.
The joint review of the applications would make it 
easier for the regulatory authorities and other stake-
holders to offer preliminary feedback regarding the 
protocols. The process of responding to queries by 
the sponsor would be made quicker while recommen-
dations would also be aggregated and acted upon by 
the sponsor at the time of the meeting. In a nutshell, 
the AVAREF meeting was not set up to coerce or 
undermine local regulatory authorities, but to sup-
port and eventually give the best opinion about pro-
tocol applications.
Lessons learnt
Joint sponsor, ethics, and regulatory reviews of study 
protocols in multi-centre studies as was done in this 
case is feasible and makes the subsequent process of 
approval faster upon receipt of the revised protocol 
and related regulatory documents.
Challenges
The different stakeholders attending would have to 
put aside other responsibilities to come and hold 
face-to-face discussions during the AVAREF meet-
ing. This was, however, extremely important given 
the gravity of the disease at hand. Stakeholders would 
have to subjugate their national viewpoint to accom-
modate the larger, regional input. This did not how-
ever happen coercively, but after discussion. For 
example, as noted above, while each country and 
authority had its standards and requirements, it was 
realised from this meeting that some of these were 
being duplicated within the same country. This meet-
ing also challenged the viewpoint that reviews always 
had to be done in sequence even in times of epi-
demics. The possibility of joint reviews at such times 
was underscored. The other viewpoint held by some 
local authorities was that the sponsor and the autho-
rities could not discuss applications together. It was 
however realised that this is very possible and does 
not necessarily bias the decision of the authorities.
Expedited review by institutional ethics and 
country-specific regulatory bodies
The initial submission to Uganda Virus Research 
Institute Research and Ethics Committee (UVRI- 
REC) took place on 13 January 2015 with request for 
expedited review. Initial feedback from UVRI-REC was 
received on 19 January 2015 which is within the coun-
cil’s stipulated 60-day timeline, i.e. the period within 
which the council indicates they must normally give 
feedback according to their guidelines [19]. This hap-
pened before the AVAREF review meeting that took 
place on the 3 and 4 February 2015. A second submis-
sion was made on 13 February 2015 after a protocol 
amendment (dated 9 February 2015) following the 
AVAREF review meeting and final approval was 
received on 5 March 2015. Application to National 
Drug Authority (NDA) was made on 5 March 2015 
with request for expedited review, and approval was 
received on 18 March 2015, which is within the 30 day 
working days timeline stipulated in the authority’s 
guidelines [20]. Application to Uganda National 
Council of Science and Technology with request for 
expedited review was made on 6 March 2015 and 
approval received on 18 March 2015, which is within 
the 10 day working days timeline stipulated in the 
council’s guidelines [20].
Rationale for the strategy
The need to conduct this research in an expedited 
manner required that approvals be attained as soon 
as possible. This was emphasised in the application 
letters. The review of the protocol in the AVAREF 
meeting by several stringent health authorities would 
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give confidence to the Ugandan authorities in the 
subsequent review process.
Lessons learnt
African regulatory authorities have the capacity to 
review research protocols in an expedited manner 
and support the implementation of important research 
including research during epidemics. Interaction 
between the sponsor, investigators, regulatory autho-
rities, and other stakeholders before formal accelerated 
protocol submissions creates mutual trust and enlight-
ens a common goal that needs to be achieved by all.
Challenges and mitigation
Expedited review carried extra costs for the sites render-
ing the process more expensive than usual. Making 
these submissions conferred more responsibility to the 
site, requiring overtime hours. The impact of extra cost 
and overtime was mitigated by the team’s experience in 
research implementation together with strong commit-
ment to making the project a success. Expedited review 
necessitated streamlined communication between the 
authorities, implementing site and sponsor, requiring 
cooperation and personnel availability from all involved 
to enable the process to flow smoothly. Communication 
between parties was almost daily and advance notifica-
tion of any regulatory submissions was provided. Also, 
the Uganda NDA was particularly eager to hold face-to- 
face meetings with the site or sponsor which greatly 
advanced understanding and resolution of issues.
Electronic data capture
The study was designed to use EDC, particularly 
utilizing Medidata Rave® [21]. This is a web-based 
clinical data management system used to capture, 
manage, and report clinical research data. The system 
provided various advantages including timely data 
entry and review, enabling quick decision-making, 
maximum control, accessibility for study team mem-
bers, flexibility, easy data extractability, and availabil-
ity of ad hoc reporting tools. It offered a full query 
and source document verification suite, which 
enabled the sponsor to conduct remote monitoring, 
supplementing onsite monitoring. This reduced the 
number of errors, queries, and protocol deviations/ 
violations. Medidata Rave ® integrates a dynamic 
laboratory range management system with laboratory 
range alerts and local references, enabling instant 
feedback whenever out of range results were entered. 
Automatic data cleaning/verification, review, locking 
and unlocking were also made possible.
Rationale for the strategy
The decision to use this system was based on the 
functions discussed above. In addition to these, the 
system would enable the sponsor to collaborate data 
collection, review, feedback, cleaning, and utilization 
including interim analyses across multiple sites.
Lessons learnt
This was the first time this study team used EDC. 
The site previously used paper-based source docu-
ments which would be entered into a database 
sometimes days after collection. However, the site 
staff adapted easily with training and orientation. 
This highlights the importance of maintaining a 
well-qualified, trained, experienced, and highly 
motivated study team. EDC is an efficient mode of 
data management and may be considered for use in 
other multi-centre trials.
Challenges
The challenges were minimal and minor. The com-
monest was staff forgetting their login credentials 
because of frequent (three-monthly) expiration of 
passwords. The effects of this were mitigated by avail-
ability of multiple staff with similar roles and avail-
ability of various Medidata customer help options 
including fax, email, and telephone. In beginning, 
no standard operating procedures were available on 
the use of EDC. EDC was set up based on guidelines 
offered by the sponsor and detailed in an EDC set up 
and user guide. However, SOPs subsequently had to 
be put in place that would apply to this and other 
studies that would later be conducted at the unit.
Competitive recruitment between sites
This trial was designed in such a way that two differ-
ent sites in different countries implemented the same 
protocol. Masaka site in Uganda was paired with 
Mwanza Intervention Trials Unit in Tanzania, with 
both sites required to recruit a total of 72 partici-
pants. While this strategy has been used elsewhere, it 
had not been used often in previous trials the unit 
participated in. The more common practice was for 
the unit to have a defined ration of participants to 
enrol.
Rationale for the strategy
This was intended to achieve rapid recruitment 
amidst anticipated ethical and operational challenges 
that could occur at either site. The other reason for 
this strategy was to generate safety and immunogeni-
city data from demographically divergent popula-
tions. Data would inform where to best conduct 
subsequent phase 2 and 3 studies.
Lessons learnt
Competitive recruitment of volunteers between dif-
ferent sites and regions can help mitigate hindrances 
related with conducting accelerated research includ-
ing challenges with ethical and regulatory clearance 
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and institution-specific operational issues. This is 
because as one site continues to work its way through 
these requirements as well as other challenges that 
may hinder recruitment, another site in a different 
country operating under different circumstances can 
manage to proceed.
Challenges
Challenges faced at one site can cause un-anticipated 
need to make re-adjustments at the other site such as 
the requirement to enrol more participants than pre-
viously planned. The site in Tanzania had issues with 
recruiting the planned number of eligible partici-
pants, requiring that the site in Uganda recruit eleven 
more participants. This inevitably came with the need 
to make budgetary and logistical adjustments.
Frequent monitoring schedule
The study monitors were required to conduct frequent 
visits according to the study protocol. Initially, the 
monitors used to spend 2 weeks at the site monthly. 
They were also required to be on site for the first 
vaccination to ensure that procedures went as required 
per protocol and offer guidance if required. There was 
a standby ‘flying squad’ of monitors from Europe that 
would come to the site whenever the workload would 
increase. In addition to these frequent onsite-monitor-
ing visits, investigational product handling aspects were 
also frequently reviewed by a separate team of monitors 
who would interact with the site pharmacy team and 
not the clinical team.
Rationale for this strategy
This accelerated Ebola vaccine development program 
was intended to generate safety and immunogenicity 
data on the vaccine candidate within a short period 
before proceeding to Phase II and III trials. This 
monitoring strategy was intended to ensure compli-
ance with the protocol, good clinical practice, and 
applicable standard operating procedures. Queries 
would also be generated and handled with no delays, 
while the presence of monitors on-site would also 
offer another quick mechanism of communication 
between the sponsor and the study team.
Lessons learnt
This strategy partly prevented the site from making 
multiple protocol deviations. We recommend that it 
is adopted even in ordinary non-accelerated clinical 
trials (even though the schedule may be less frequent) 
to avoid resource wastage, recruitment of ineligible 
participants and other issues that come along with 
protocol deviations.
Challenges
The study staff had to apportion time appropriately 
between the strenuous recruitment activities and attend-
ing to the monitoring queries. More staff were recruited, 
which in turn increased the cost of running this study.
Involvement of the community advisory board
The MRC/UVRI & LSHTM Uganda Research Unit 
routinely utilises support from the CAB before and 
during the conduct of its research studies. This board 
is comprised of 20 members including political, admin-
istrative, religious, and cultural leaders, medical profes-
sionals, local media, community-based organisations, 
people living with HIV/AIDS, study participants, as 
well as representatives from the general community.
The CAB was convened for various meetings 
during which different aspects of Ebola virus dis-
ease were discussed, including the status of the 
Western Africa epidemic and the need for a vaccine 
to curb the epidemic. Information about the 
VAC52150EBL1004 protocol was shared and even-
tually, the study team received feedback from the 
CAB with members advising on the practicality of 
implementing the study in this setting. The CAB 
overwhelmingly agreed that this study was imple-
mentable in this setting and that results gained 
would be of utmost value to everyone especially in 
Uganda where several Ebola outbreaks had 
occurred. Particularly important, the CAB advised 
that given the nature of the study with stringent 
eligibility requirements such as ability to read and 
write, it would be wise to engage the wider com-
munity, but particularly giving extra focus to edu-
cated communities including university students, 
health workers, and teachers.
Rationale of the strategy
Previous controversies in the conduct of biomedical 
research worldwide led to calls from bioethicists to 
mandate community involvement in decision-mak-
ing about the ethical conduct of health research 
[22,23]. Participation of community representatives 
at different levels of research implementation is 
required to ensure that communities are not 
exploited [24]. Other benefits of having community 
representatives included: help discover what the 
specific local concerns were, squash rumours, enlist 
support of community leaders, express the commu-
nity’s desire to participate in the research, elicit 
information from researchers that the community 
may need to know about the study, participation in 
dissemination of research findings, among others 
[25]. CABs have been used to provide these func-
tions at the MRC/UVRI & LSHTM Uganda 
Research Unit in multiple research projects and 
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this relationship over the years has contributed to 
successful implementation of research.
Lessons learnt
While the practice of using CABs has been prevalent 
over the years at the unit, its usefulness in this study 
needs to be commended. The idea of focusing on 
educated communities such as university students, 
health workers, and teachers was forwarded by the 
CAB. The functions of a CAB remain paramount 
even in the implementation of accelerated research 
and especially research on diseases that spread an 
aura of fear into communities.
Challenges
The limitation on time implied that meetings with the 
CAB had to be organised urgently. However, flexibil-
ity from both the researchers and CAB made these 
meetings successful. Study personnel also had to 
communicate study information in a manner that 
CAB members of diverse backgrounds could compre-
hend. With the help of various communication aids 
and extensive experience on the side of both 
researchers and the CAB, key messages were commu-
nicated by the study team and clearly understood by 
the CAB members.
The phased study information-sharing approach 
in community engagement and participant 
recruitment
The site used a phased study information-sharing 
approach culminating in screening, with all sessions 
including screening occurring between April and 
August 2015. We have referred to this approach as 
‘phased’ because information was shared in different 
sessions that built onto one another regarding infor-
mation shared. We hereby describe the issues dis-
cussed in each session.
Session 1: These sessions were held at centres in 
the community including teaching institutions, health 
facilities – particularly targeting health workers; and 
community halls – targeting other community mem-
bers. These sessions focussed on haemorrhagic fever 
diseases with emphasis on Ebola virus disease (EVD). 
Issues discussed included what EVD is, the case fatal-
ity rates, its history with emphasis on previous epi-
demics in Uganda, modes of transmission, signs and 
symptoms, and how it can be prevented. It was 
stressed that new interventions were required, includ-
ing the use of vaccines, to prevent and treat haemor-
rhagic diseases. At the end of the presentations, 
attendees had the opportunity to ask questions. 
Those interested in learning more about potential 
treatments and vaccines were requested to register 
for another session. Overall, 270 potential volunteers 
attended these sessions, 177 of these (65.5%) being 
male, with each session registering an average of 50 
potential volunteers.
Session 2: These sessions were held at the MRC/ 
UVRI & LSHTM Uganda Research Unit site in 
Masaka. Of the 270 potential volunteers who 
attended the first session, 233 (86.3%) returned for 
the second session, 149 (63.9%) being male. Issues 
discussed in this session included potential treat-
ments and vaccines. Emphasis was on vaccines, 
including a review of the different vaccine types, 
how vaccines are manufactured, and progression of 
trials through pre-clinical to human stages. The 
VAC52150EBL1004 trial was briefly discussed, 
including how this had so far progressed through 
the preclinical development stages, and preliminary 
results from a similar study implemented under a 
different protocol but using the same vaccine candi-
dates in the UK [26]. Volunteers could ask questions 
at the end of the presentations, after which registra-
tion was open for those interested in returning for a 
final session.
Session 3: This session also took place at the study 
site. Out of the 233 potential volunteers who attended 
the second session, 180 returned for this session, 114 
(63%) being male. Each member was individually taken 
through the study participant information sheets (PIS) 
and a consent form by designated study staff. This was 
followed by answering a test of understanding compris-
ing 10 objective questions in the same language as the 
PIS and consent form (English or Luganda). Volunteers 
that scored at least 9/10 on at most two attempts were 
given the opportunity to sign the consent form if they 
wanted to proceed with the study. Out of 180 volun-
teers, 176 (98%) passed the test of understanding and all 
of these signed the consent form.
Participants that offered consent proceeded to a 
screening phase. Of the 176 that entered screening, 47 
participants met the eligibility criteria and were 
enrolled into the study (Screening to enrolment 
ratio of 4:1). The site completed this process in 
approximately 5 months.
Rationale of the strategy
Given the sensitivity around the idea of vaccination 
against an extremely deadly disease using genetically 
modified virus components, potential volunteers 
needed time and multiple interactions to correctly pro-
cess the complicated information. We considered it 
necessary to give them time to think critically about 
the information and ask questions before making a final 
decision to participate in the study. Due to the complex-
ity of the information, we considered that breaking it 
down would make it easier to communicate and under-
stand. We also considered that those that would attend 
the sessions but not eventually participate would gen-
erally be educated about EVD; therefore, the sessions 
also served as Ebola awareness campaigns.
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Lessons learned
This strategy made it easier to communicate sensitive 
information and eventually enabled the site to com-
plete recruitment in only 5 months. The idea of 
initially meeting potential participants in the commu-
nity made it easier for many to attend without neces-
sarily having them feel like they were mandated to 
participate in the trial.
Challenges
This strategy was expensive due to the requirement to 
reimburse all attendees. In addition, the site had to 
get ethical approval for all the materials that were 
used during these sessions.
Conclusion
The use of well-thought methods designed a priori by 
the sponsor and site enabled the team at MRC/UVRI 
& LSHTM Uganda Research Unit to successfully 
implement this phase one research project in an 
accelerated manner and within the stipulated time-
lines. Emerging and re-emerging disease threats that 
require the development of more potent drugs and 
vaccines are increasing. Fortunately, some outbreaks 
take a short period to abate or stop completely, how-
ever that would mean missing the opportunity to 
evaluate new interventions. Research teams need to 
embrace efficient strategies to implement research 
within the small window of disease outbreaks.
Recommendations
We recommend that other research teams planning 
to participate in the implementation of accelerated 
research especially in resource-limited settings con-
sider utilising similar strategies. Accelerated research 
requires that regulatory authorities and research 
teams establish strong working relationships so that 
approvals are attained promptly. Community engage-
ment remains key, and methodologies to communi-
cate sensitive research issues have to be considered in 
order to deliver the messages appropriately. The 
implementation of this kind of research requires 
that research facilities adapt to the use of electronic 
data collection tools, while continuous oversight of 
trials through frequent monitoring makes data clean-
ing a continuous and timely process and reduces on 
occurrence of protocol deviations.
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Paper context
The 2013-2016 Ebola epidemic in West Africa required 
accelerated development of interventions including vac-
cines. MRC/UVRI & LSHTM Uganda Research Unit 
implemented the VAC52150EBL1004 trial in an accelerated 
manner, using various strategies such as holding the 
AVAREF review meeting; expedited review by institutional 
regulatory authorities, and involvement of a community 
advisory board. This enabled enrolment to be completed 
within 5 months. The use of similar strategies in other 
settings may enable accelerated research in epidemics.
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Appendix 1.  
Study flow diagram
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Appendix 2.  
Table summarising strategies
Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA- 
BN-Filo two-dose Ebola vaccine clinical trial in Uganda
Strategy Rationale for strategy Impact of using strategy Lessons learnt Challenges





-Enlist the support of 
external agencies such 
as the Food and Drug 
Administration in 
conducting review of 
applications. 
-Harmonise the roles of 
regulatory authorities in 
the conduct of reviews 
thereby avoiding 




opinions about this type 
of research. 
-Inform western partners 
about local/regional 
requirements in the 
conduct of research. 
-Enable joint review of 
protocols and enable 
quicker response to 
queries. 
-Communicate 




easier and quicker. 
-Clarified local/regional 
needs to the sponsor.
-Underscored the importance of 
joint protocol review 
especially in the setting of a 
wide spread epidemic.
-Time commitment from all 
stakeholders. 
-Requirement to harmonise 
requirements.




Need to have research 
conducted very first to 
respond to an 
emergency at hand.
Enabled research to 
begin quickly.
-Capacity is available among 
local regulatory authorities to 
do expedited review. 
-Interactions between the 
sponsor and authorities 
creates mutual trust.
-Higher fees had to be paid by 
the site to the authorities for 
expedited review. 
-More commitment than usual 
required of sites to make 
submissions quickly.
(3) Electronic data cap-
ture (EDC).
-Need for timely data entry 
and review. 
-Need for quick data 
guided decision making. 
-Need to easily generate 
and respond to queries.
-Timely data entry and 
review enabled. 
-Enabled real time 







-Underscored the use of similar 
platforms in data 
management. 
-Advantages realised including 
remote monitoring make the 
use of this system extremely 
necessary, especially in times 
of epidemics/pandemics 
where movement to and 
research sites may not be 
very easy.
-Staff occasionally forgot log in 
credentials. 
-Data locks would require that 
individuals with unlocking 
rights are contacted 
whenever changes had to be 
made to data. A bit of time 
was wasted during such 
intervals. 
-Standard operating 
procedures for use of EDC 
were initially not available. 




-More generalizable data 
taking advantage of 
demographic variations 
would be generated. 
-Challenges in recruitment 
at one site would be 
counteracted.
When the Mwanza site 
got challenges, our 
Ugandan site was in 
position to recruit an 
extra number of 
participants.
Competitive recruitment can 
help mitigate challenges 
encountered at one site by 
having the other site make re 
adjustments.
Need to quickly plan and make 
budgetary adjustments.
(5) Frequent study mon-
itoring schedule.
-Ensure compliance to the 
protocol, GCP, and 
applicable standard 
operating procedures. 
-Timely generation and 
response to queries.
Enabled generation of 
timely clean data for 
decision making.
-This strategy can help reduce 
on the occurrence of protocol 
deviations/violations which 
could have serious 
consequences for participants 
and the study in general.
-Increased trial running costs. 
-More commitment required 
from staff attending to 
issues/sorting queries.
(6) Involvement of a 
community advisory 
board (CAB).
-Prevent exploitation of 
participating 
communities. 
-Act as a bridge linking the 
research site and the 
community. 
-Make an input in the 
design of the study 
especially as regards the 
recruitment strategy.
-The CAB gave 




by the CAB. 




The CAB is an incredible 
resourceful group whose 
inputs make the research 
process easier.
-Money had to be spent in 
organising multiple sessions 
with the CAB.
(Continued )
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(Continued). 
Strategy Rationale for strategy Impact of using strategy Lessons learnt Challenges




nity engagement and 
participant recruit-
ment.
-Need to break down the 
complicated scientific 
messages into ‘smaller 
chunks’ that potential 
participants would 
understand. 
-It would be necessary for 
potential participants to 
be given time to 
deliberate on 
information passed onto 
them. 
-Potential participants 
needed to be given 
adequate time to make 
an informed decision to 
participate in the study.
-It became easier to 
communicate the 
research messages 
after breaking them 
into ‘smaller chunks’. 
-Those that eventually 
got enrolled 
understood the study 
very well as 
demonstrated on the 
test of understanding. 
-General messages 
related to Ebola virus 
disease were given to 
community members.
-This approach is a very good 
approach for a study that 
involves a lot of detail. 
-Starting information sharing in 
the community ensures that 
only interested potential 
participants come to the site.
-Organising multiple sessions 
increases financial 
expenditure. 
-Ethical approval was required 
for all communication aids. 
Finding ideal settings in the 
community where 
presentations could be 
made was sometimes 
challenging.
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